• Follow
  • Follow
  • Follow
  • About
    • About
    • Management Team
    • Board of Directors
  • Our Businesses
    • Active Ingredients (Ceapro)
    • Oral Thin Film (Nualtis)
  • Technologies
  • Investors and News
    • Press Releases
    • Events & Presentations
    • Investor Contacts
    • Stock Information
    • Financial Filings
      • SEC Filings
      • SEDAR
    • Governance
      • Corporate Governance
      • Board Committees
      • Board Diversity Matrix
      • Clawback Policy
      • Annual Reports
    • Email Alerts
  • Contact

Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

by jtcir-auto | Jan 5, 2021 | Press Releases

CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr....

Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin

by jtcir-auto | Dec 7, 2020 | Press Releases

CHARLESTON, S.C., Dec. 07, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...

Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin

by jtcir-auto | Dec 7, 2020 | Press Releases

CHARLESTON, S.C., Dec. 07, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...

Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin

by jtcir-auto | Nov 16, 2020 | Press Releases

– Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million  - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02 (“Study P02”) clinical trial costs for...

Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin

by jtcir-auto | Nov 16, 2020 | Press Releases

– Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million  - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02 (“Study P02”) clinical trial costs for...

Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update

by jtcir-auto | Nov 6, 2020 | Press Releases

– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021- Continue to advance discussions to secure a commercialization partner for macimorelin in Europe and other key global markets- Ongoing evaluations...
« Older Entries
Next Entries »

Recent Posts

  • COSCIENS Biopharma Inc. Reports Q3 2026 Results and Provides Update On Convertible Debenture Offering
  • COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS ACQUIRES NUALTIS CORP.
  • COSCIENS Biopharma Inc. Reports Q2 2026 Results

Recent Comments

No comments to show.
Latest News:

Stock Info

TSX:

 

 

Sign Up For Alerts

Click Here and Stay Up To Date With Cosciens News and Events

 

Contact Us

© 2026 COSCIENS BIOPHARMA   All Rights Reserved   Terms and Conditions  Privacy Policy

  • Follow
  • Follow
  • Follow